Natus Medical Incorporated NTUS
Set alert
32.96 0.00 0.00%
As of Apr 24, 3:47 PM ET
32.84 Day range 33.07
52-week range unavailable
- Open
- 32.90
- Prev close
- 32.96
- Mkt cap
- 0
- Vol
- 132.70K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 32.84
- High
- 33.07
- Forward P/E
- 20.99
- Beta
- 0.23
- Short ratio
- 4.11
- Inst. own
- 95.20%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 4, 2022
- 50-d avg
- 32.61
- 200-d avg
- 27.38
- 1y target
- 0.00
1M chart
Signals (13)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Jul 19, 2022 | 4 years ago |
| SMA: Bullish | Jul 15, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 14, 2022 | 4 years ago |
| SMA: Bearish | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jun 30, 2022 | 4 years ago |
| SMA: Bearish | Jun 29, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 27, 2022 | 4 years ago |
| SMA: Bullish | Jun 24, 2022 | 4 years ago |
| SMA: Bullish | Jun 23, 2022 | 4 years ago |
| SMA: Bearish | Jun 22, 2022 | 4 years ago |
| SMA: Bearish | Jun 22, 2022 | 4 years ago |
| SMA: Bullish | Jun 21, 2022 | 4 years ago |
| SMA: Bullish | Jun 21, 2022 | 4 years ago |
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (-1m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 1
- 2 months ago 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.32 | 0.32 – 0.32 | 0.29 | +10.3% | 120.40M | +3.8% | 1 |
| Next quarter | 0.37 | 0.37 – 0.37 | 0.28 | +32.1% | 123.70M | +8.6% | 1 |
| Current year | 1.44 | 1.44 – 1.44 | 1.20 | +20.0% | 495.00M | +4.6% | 1 |
| Next year | 1.57 | 1.57 – 1.57 | 1.44 | +9.0% | 517.20M | +4.5% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2, 2017 | Raymond James | Downgrade | Outperform | Market Perform |
| Oct 4, 2016 | Benchmark | Initiated | — | Buy |
| Sep 13, 2016 | Raymond James | Upgrade | Market Perform | Outperform |
| Apr 5, 2016 | Roth Capital | Maintained | — | Buy |
| Oct 7, 2014 | William Blair | Downgrade | Market Perform | Outperform |
| May 6, 2013 | CJS Securities | Initiated | — | Market Perform |
| May 2, 2013 | Raymond James | Upgrade | Market Perform | Outperform |